Linker Information
General Information of This Linker
| Linker ID |
LIN0QRMAF
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
L32 linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C178H321N19O73
|
|||||
| Isosmiles |
COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(N(CC1=CC(NC([C@@H](NC([C@H](NC(CNC(OCCN2N=NC(COC(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCN3C(C=CC3=O)=O)=O)C(N[C@H](C(N[C@@H](CCCNC(N)=O)C(NC4=CC(CN(C)C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=C(C=C4)C)=O)=O)C(C)C)=O)=O)=C2)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)=CC=C1C)C)=O
|
|||||
| InChI |
InChI=1S/C178H321N19O73/c1-150(2)168(173(207)187-159(16-13-28-182-175(179)209)170(204)185-156-20-18-152(5)154(143-156)146-194(7)164(200)25-33-216-42-46-222-54-58-228-66-70-234-78-81-239-87-89-243-95-97-247-103-105-251-111-113-255-119-121-259-127-129-263-135-137-267-141-139-265-133-131-261-125-123-257-117-115-253-109-107-249-101-99-245-93-91-241-85-83-237-75-73-231-63-61-225-51-49-219-39-37-213-9)190-163(199)145-184-177(211)269-36-30-196-148-158(192-193-196)149-270-178(212)189-161(15-11-12-27-181-162(198)24-32-215-41-45-221-53-57-227-65-69-233-77-80-236-72-68-230-60-56-224-48-44-218-35-31-197-166(202)22-23-167(197)203)172(206)191-169(151(3)4)174(208)188-160(17-14-29-183-176(180)210)171(205)186-157-21-19-153(6)155(144-157)147-195(8)165(201)26-34-217-43-47-223-55-59-229-67-71-235-79-82-240-88-90-244-96-98-248-104-106-252-112-114-256-120-122-260-128-130-264-136-138-268-142-140-266-134-132-262-126-124-258-118-116-254-110-108-250-102-100-246-94-92-242-86-84-238-76-74-232-64-62-226-52-50-220-40-38-214-10/h18-23,143-144,148,150-151,159-161,168-169H,11-17,24-142,145-147,149H2,1-10H3,(H,181,198)(H,184,211)(H,185,204)(H,186,205)(H,187,207)(H,188,208)(H,189,212)(H,190,199)(H,191,206)(H3,179,182,209)(H3,180,183,210)/t159-,160-,161-,168+,169-/m0/s1
|
|||||
| InChIKey |
UADHSBMXVUPNCQ-OKBJXYBTSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
3895.586
|
Polar area
|
1016.19
|
||
|
Complexity
|
.
|
xlogp Value
|
1.12934
|
|||
|
Heavy Count
|
270
|
Rot Bonds
|
209
|
|||
|
Hbond acc
|
76
|
Hbond Donor
|
13
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
CD74 Milatuzumab DANAPAE152C S375C-P1-L32-P2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.247 nM
|
High CD74 expression (CD74 +++) | ||
| Method Description |
CD74 Milatuzumab DANAPAE152C S375C-P1-L32-P2 was tested in EOL-1
|
||||
| In Vitro Model | Chronic eosinophilic leukemia | EoL-1 cells | CVCL_0258 | ||